French Pharma Stock News

Edenred (ENXTPA:EDEN) has drawn fresh investor attention after issuing a €500 million, 7 year bond at a 3.75% coupon, with demand reportedly more than three times the offer size. See our latest analysis for Edenred. The bond deal comes after a softer period for the equity, with the share price at €17.97 and a 90 day share price return of a 12.77% decline. The 1 year total shareholder return of a 39.92% decline and 5 year total shareholder return of a 56.75% decline suggest longer term...

2CRSI (EPA:AL2SI) has had a rough three months with its share price down 16%. But if you pay close attention, you might...

Key Insights Icade's significant private companies ownership suggests that the key decisions are influenced by...

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...

SCOR (EPA:SCR) has had a rough three months with its share price down 7.0%. But if you pay close attention, you might...

It's not a stretch to say that Ramsay Générale de Santé SA's ( EPA:GDS ) price-to-sales (or "P/S") ratio of 0.2x right...

Airbus (ENXTPA:AIR) is back in focus after reporting 793 commercial aircraft deliveries for 2025, along with 1,000 new orders and a record backlog of 8,754 jets, including 1,124 widebodies. See our latest analysis for Airbus. The latest aircraft delivery beat and record backlog sit against a mixed price picture, with a recent 9.86% 1 month share price return but a 2.16% 1 day pullback as investors digest new alliances in quantum computing and fuel cell technology. Overall, Airbus combines...

If you are wondering whether TotalEnergies at around €57.06 is offering fair value or a potential mispricing, you are in the right place for a clear look at what the current market price might be saying. The share price has recent returns of 6.6% over 7 days, 2.8% over 30 days, 1.7% year to date, 8.4% over 1 year and 12.7% over 3 years, with a very large 5 year return that suggests long term holders have seen strong compounding. Recent coverage around large integrated energy companies has...

Air France-KLM (ENXTPA:AF) is back in focus after a period in which the share price has moved lower over the week, month and past 3 months, despite a positive 1 year total return. See our latest analysis for Air France-KLM. That recent share price pressure, including a 5.15% 1 day share price return decline and weaker 7 day and 90 day share price returns, contrasts with a 50.18% 1 year total shareholder return. This suggests earlier optimism has cooled and investors are reassessing risk and...

If you are wondering whether Vinci at €116.75 is offering fair value or a margin of safety, you are not alone. This article focuses squarely on what the current price might mean for investors. The stock has seen a 6.0% decline over the last 7 days and a 2.8% decline over the last 30 days, while still showing a 21.6% return over 1 year, 26.5% over 3 years and 67.6% over 5 years. This raises questions about how the recent pullback fits into the longer term picture. Recent news flow around...

In the first quarter of fiscal 2026, Sodexo reported past consolidated revenue of €6,260 million, slightly below the prior year's €6,403 million. Ahead of its Net Zero Carbon 2040 goal, Sodexo was recently named to CDP’s Climate A List, distinguishing it as the only company in its sector to achieve this environmental leadership rating. Next, we’ll examine how Sodexo’s CDP Climate A List recognition, alongside its broader sustainability commitments, may influence its investment narrative. The...

LVMH Moët Hennessy - Louis Vuitton Société Européenne (ENXTPA:MC) is back in focus after recent trading left the share price near €637.90, inviting investors to reassess the luxury group’s longer term return profile. See our latest analysis for LVMH Moët Hennessy - Louis Vuitton Société Européenne. Recent trading has been slightly softer, with a 1 day share price return of 1.35% and a 7 day share price return of 1.37%. The 1 year total shareholder return of 2.51% contrasts with a 3 year total...

In recent days, L'Oréal S.A. completed a series of euro-denominated bond issues totaling €1.75 billion, including floating-rate notes due 2028 and fixed-rate bonds maturing between 2029 and 2032, to help fund its planned additional 10% stake in Galderma and other corporate purposes. At the same time, L’Oréal’s partnership with iSMART Developments on flexible LED masks and its CES 2026 award-winning beauty tech devices highlight how the group is extending beyond traditional cosmetics into...

Sartorius Stedim Biotech S.A.'s ( EPA:DIM ) price-to-earnings (or "P/E") ratio of 79.2x might make it look like a...

Eramet recently reported strong results in the 2025 Carbon Disclosure Project cycle, securing A- scores for both Climate Change and Water Security as part of its “Act for Positive Mining” CSR roadmap. This recognition underscores Eramet’s progress in sustainable water management, including more reliable data, comprehensive water balances, and alignment with leading international standards. We’ll now examine how Eramet’s stronger CDP scores and environmental credentials may shape the...

As the European markets continue to show optimism with major stock indexes rising, investors are keenly observing opportunities across various sectors. Penny stocks, often seen as a relic of past market eras, still hold potential for growth by offering affordability and the promise of future gains when supported by strong financials. In this article, we spotlight three European penny stocks that exemplify this potential through their robust balance sheets and promising prospects.

Leerink Partners recently initiated coverage on Inventiva with an Outperform rating and a US$12.00 price target, following earlier positive views from UBS and Wolfe Research on the company’s lead NASH/MASH candidate lanifibranor. At the same time, Inventiva secured about US$172.5 million in planned equity financing alongside a US$150 million ADS offering, reinforcing funding for the fully enrolled Phase 3 NATiV3 trial in a disease area that still has no approved therapies. We’ll now examine...

In early January 2026, BrightInsight reported improved adherence and persistence from its Patient App for a key Sanofi–Regeneron biologic, while Sanofi also expanded its immunology footprint through a potential US$2.56 billion-plus autoimmune collaboration with Earendil Labs and advanced Tzield via US priority review in young children and European approval to delay type 1 diabetes progression. These developments highlight how Sanofi is pairing digital tools with regulatory progress in...

As European markets continue to show optimism, with the STOXX Europe 600 Index rising by 2.27% amid a favorable economic backdrop and positive company earnings, investors are exploring various opportunities across the continent. Penny stocks, while often considered a niche area of investment, still offer potential for growth, particularly when these smaller or newer companies demonstrate strong financial health. In this article, we will explore three penny stocks that may combine balance...

In recent weeks, the European market has shown signs of optimism, with the pan-European STOXX Europe 600 Index rising by 2.27%, buoyed by stronger-than-expected industrial production in key economies like Germany and a favorable interest rate environment. As investors navigate this landscape, identifying stocks that demonstrate resilience and growth potential can be crucial, especially those that may not yet have captured widespread attention but are well-positioned to benefit from these...

What ABIVAX Société Anonyme’s recent performance means for investors ABIVAX Société Anonyme (ENXTPA:ABVX) has drawn attention after a period where its share price shows a mix of shorter term softness and stronger past 3 months and 1 year returns, inviting a closer look at fundamentals. See our latest analysis for ABIVAX Société Anonyme. Over the past year, ABIVAX Société Anonyme’s share price has been volatile, with a recent 3 month share price return of 25.6% contrasting with a year to date...

Lumibird's (EPA:LBIRD) stock is up by a considerable 17% over the past three months. However, we decided to pay...

Key Insights Significant control over Métropole Télévision by private companies implies that the general public has...

Robertet's (EPA:RBT) stock up by 9.4% over the past three months. Given that the market rewards strong financials in...